PPT-Fingolimod

Gilenya Presented by Matthew Brickey Tim Robinson Tom McGinnis and Katie Youmans Outline D isease Multiple Schlerosis D iscovery of FingolimodGilenya S ynthesis and lead modification. Study Design. 24-month, RCT of . fingolimod. 0.5 mg and 1.25 mg vs placebo. 3 years into the study, 1.25 mg discontinued and patients placed on 0.5 mg in blinded manner . R. elapsing-remitting MS patients . Treatments Personalized Strategies. Dr. Suhail Al-Shammri. Associate Professor& Head Division of Neurology, . Mubark. Al . Kabir. Hospital. Overview. The diagnostic criteria of multiple sclerosis( MS). Brickey. , Tim Robinson, Tom McGinnis, and Katie Youmans. Outline. D. isease: Multiple . Schlerosis. D. iscovery of . Fingolimod-Gilenya. S. ynthesis and lead modification. Mechanism of action. Pharmacology . AL . Ghazawi. Associated Professor. Neurologist. MRCP,FRCP UK. What is Multiple Sclerosis (MS)?. 1-. CHRONIC Autoimmune demyelination. disease of. CNS:. a- brain. b-optic nerve. c- and spinal cord. Goals of Disease Management. Reduce relapses and prevent and/or slow progression. Treat serious relapses. Assess and manage symptoms. Improve the patient’s and family’s quality of life. Relapses and Relapse Management. sclerosis (MS. ) . is an inflammatory disease of the central nervous system (CNS), variable in symptoms and presentation. Multiple describes the number of CNS lesions, and sclerosis refers to the demyelinated lesions, today called plaques.. CIS. RIS. CDMS. SPMS. From RIS to first relapse. Younger age. Male sex. Spinal cord lesions. Long-term disability progression. T2 and T1 lesion volume. Whole brain / GM volume changes. Cortical lesion volume / number.